These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29792309)

  • 41. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
    Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
    Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
    Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma.
    Matsushita K; Okuda T; Mori S; Konno M; Eguchi H; Asai A; Koseki J; Iwagami Y; Yamada D; Akita H; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Kasahara Y; Morihiro K; Satoh T; Doki Y; Mori M; Ishii H; Obika S
    ChemMedChem; 2019 Aug; 14(15):1384-1391. PubMed ID: 31207139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
    Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ultrasound-induced Cavitation enhances the efficacy of Chemotherapy in a 3D Model of Pancreatic Ductal Adenocarcinoma with its microenvironment.
    Leenhardt R; Camus M; Mestas JL; Jeljeli M; Abou Ali E; Chouzenoux S; Bordacahar B; Nicco C; Batteux F; Lafon C; Prat F
    Sci Rep; 2019 Dec; 9(1):18916. PubMed ID: 31831785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
    Molejon MI; Tellechea JI; Loncle C; Gayet O; Gilabert M; Duconseil P; Lopez-Millan MB; Moutardier V; Gasmi M; Garcia S; Turrini O; Ouaissi M; Poizat F; Dusetti N; Iovanna J
    Oncotarget; 2015 Apr; 6(10):7408-23. PubMed ID: 25797268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.
    Li J; Qu X; Tian J; Zhang JT; Cheng JX
    PLoS One; 2018; 13(2):e0193318. PubMed ID: 29489864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
    Binenbaum Y; Fridman E; Yaari Z; Milman N; Schroeder A; Ben David G; Shlomi T; Gil Z
    Cancer Res; 2018 Sep; 78(18):5287-5299. PubMed ID: 30042153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma.
    Lundy J; Gearing LJ; Gao H; West AC; McLeod L; Deswaerte V; Yu L; Porazinski S; Pajic M; Hertzog PJ; Croagh D; Jenkins BJ
    Oncogene; 2021 Oct; 40(41):6007-6022. PubMed ID: 34400766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
    Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
    PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
    Liu T; Fang Y; Zhang H; Deng M; Gao B; Niu N; Yu J; Lee S; Kim J; Qin B; Xie F; Evans D; Wang L; Lou W; Lou Z
    Cancer Res; 2016 Feb; 76(3):572-81. PubMed ID: 26676747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
    Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
    Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.
    Avan A; Caretti V; Funel N; Galvani E; Maftouh M; Honeywell RJ; Lagerweij T; Van Tellingen O; Campani D; Fuchs D; Verheul HM; Schuurhuis GJ; Boggi U; Peters GJ; Würdinger T; Giovannetti E
    Cancer Res; 2013 Nov; 73(22):6745-56. PubMed ID: 24085787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
    Wang K; Baldwin GS; Nikfarjam M; He H
    Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Biol Ther; 2010 Jul; 10(1):99-107. PubMed ID: 20495354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.